Shionogi To Submit NDA For Flu Drug Premivir In Japan
This article was originally published in PharmAsia News
Executive Summary
Shionogi announced the company is preparing for a NDA submission in Japan for anti-viral flu agent and neuraminidase inhibitor premivir within the year. The Osaka-based company said a domestic clinical trial of the drug has shown promising results and it is conducting a thorough data analysis and preparing application documents for a NDA submission. Shionogi obtained the exclusive rights to premivir in Japan from BioCryst Pharmaceuticals of the U.S, where the drug is under Phase II development. (Click here for more - Japanese language